Skip to content

Study · Non-randomized trial · 2013

7 results

One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.

Rosenstock J, Rodbard HW, Bain SC, D'Alessio D, Seufert J, Thomsen AB, Svendsen CB, DeVries JH

Journal of diabetes and its complications6 Jun 2013Cited by 37 (Europe PMC)

PMID23746555 (opens in a new tab)DOI10.1016/j.jdiacomp.2013.04.008 (opens in a new tab)PepBankPUB-23746555
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on metformin, adding liraglutide 1.8 mg for 12 weeks improved HbA1c from 8.3% to 7.6% (-0.6%).

    In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide added to metformin lowered HbA1c from 8.3% to 7.6%.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change during 12-week liraglutide run-in
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 12 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.6%
    run-in

    Source sentences

    Summary
    Run-in HbA1c improvement from 8.3% to 7.6% (-0.6%)
    1 context sentence
    Summary · context
    Patients previously uncontrolled on metformin±sulfonylurea with HbA1c ≥7.0% after 12 weeks of adding liraglutide 1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to 52 weeks' open-label add-on detemir (randomized treatment [RT] group; n=162) or continuation without detemir…
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on metformin, adding liraglutide 1.8 mg for 12 weeks led to a weight loss of 3.5 kg.

    In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide added to metformin led to 3.5 kg of weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change during 12-week liraglutide run-in
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg · 12 weeksAs given in this study (human).

    Measurements

    Weight change
    −3.5 kg
    run-in

    Source sentences

    Summary
    Run-in weight loss (-3.5kg)
    1 context sentence
    Summary · context
    Patients previously uncontrolled on metformin±sulfonylurea with HbA1c ≥7.0% after 12 weeks of adding liraglutide 1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to 52 weeks' open-label add-on detemir (randomized treatment [RT] group; n=162) or continuation without detemir…

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes with HbA1c of 7.0% or more after liraglutide plus metformin, add-on insulin detemir lowered HbA1c more than continuing without detemir over 52 weeks (estimated treatment difference -0.51%).

    In plain wordsIn adults with type 2 diabetes on liraglutide and metformin, adding insulin detemir lowered HbA1c more than continuing without detemir.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 52 weeks, add-on detemir versus no detemir
    Study

    n: not reported in source

    Comparator
    Continuation without detemir (RC group)
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Estimated treatment difference
    −0.51%
    RT versus RC

    Source sentences

    Summary
    Run-in HbA1c improvement from 8.3% to 7.6% (-0.6%) was further enhanced in the RT group (-0.50%) and maintained in the RC group (+0.01%) over 52 weeks; estimated treatment difference (ETD)[95%CI]: -0.51 [-0.70;-0.31]; P<0.0001.
    1 context sentence
    Summary · context
    Patients previously uncontrolled on metformin±sulfonylurea with HbA1c ≥7.0% after 12 weeks of adding liraglutide 1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to 52 weeks' open-label add-on detemir (randomized treatment [RT] group; n=162) or continuation without detemir…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on liraglutide plus metformin, more patients with add-on detemir (52%) than without detemir (22%) reached HbA1c below 7.0% at 52 weeks.

    In plain wordsMore adults on liraglutide and metformin reached HbA1c below 7.0% when insulin detemir was added (52%) than without it (22%).

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion with HbA1c below 7.0% at 52 weeks
    Study

    n: not reported in source

    Comparator
    Continuation without detemir (RC group)
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Responders HbA1c <7.0%
    52%
    RT group
    Responders HbA1c <7.0%
    22%
    RC group

    Source sentences

    Summary
    More RT (52%) than RC patients (22%) achieved HbA1c <7.0% at 52 weeks (P<0.0001).
    1 context sentence
    Summary · context
    Patients previously uncontrolled on metformin±sulfonylurea with HbA1c ≥7.0% after 12 weeks of adding liraglutide 1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to 52 weeks' open-label add-on detemir (randomized treatment [RT] group; n=162) or continuation without detemir…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on liraglutide plus metformin, run-in weight loss was maintained with add-on detemir (-0.05 kg) and enhanced without detemir (-1.02 kg); the treatment difference was 0.97 kg.

    In plain wordsIn adults on liraglutide and metformin, weight loss was kept with added insulin detemir but grew further without detemir.

    Peptide
    Liraglutide
    Outcome
    IncreaseBody weight change at 52 weeks, add-on detemir versus no detemir
    Study

    n: not reported in source

    Comparator
    Continuation without detemir (RC group)
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Estimated treatment difference
    0.97 kg
    RT versus RC

    Source sentences

    Summary
    Run-in weight loss (-3.5kg) was maintained in the RT (-0.05kg) and enhanced in the RC group (-1.02kg) after 52 weeks; ETD [95%CI]: 0.97 [0.04;1.91]; P=0.04.
    1 context sentence
    Summary · context
    Patients previously uncontrolled on metformin±sulfonylurea with HbA1c ≥7.0% after 12 weeks of adding liraglutide 1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to 52 weeks' open-label add-on detemir (randomized treatment [RT] group; n=162) or continuation without detemir…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 06HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on liraglutide plus metformin, no major hypoglycemia occurred in the groups over 52 weeks.

    In plain wordsIn adults on liraglutide and metformin, no major low blood sugar events occurred in any group.

    Peptide
    Liraglutide
    Outcome
    No significant changeMajor hypoglycemia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    No major hypoglycemia occurred; minor hypoglycemia rates were low across groups (0.034-0.228 events/patient-year).
    1 context sentence
    Summary · context
    Patients previously uncontrolled on metformin±sulfonylurea with HbA1c ≥7.0% after 12 weeks of adding liraglutide 1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to 52 weeks' open-label add-on detemir (randomized treatment [RT] group; n=162) or continuation without detemir…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 07HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on liraglutide plus metformin, minor hypoglycemia rates were low across groups (0.034-0.228 events per patient-year).

    In plain wordsIn adults on liraglutide and metformin, minor low blood sugar events were rare in all groups.

    Peptide
    Liraglutide
    Outcome
    No significant changeMinor hypoglycemia rate
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Minor hypoglycemia rate
    0.034 to 0.228 events/patient-year
    across groups

    Source sentences

    Summary
    minor hypoglycemia rates were low across groups (0.034-0.228 events/patient-year).
    1 context sentence
    Summary · context
    Patients previously uncontrolled on metformin±sulfonylurea with HbA1c ≥7.0% after 12 weeks of adding liraglutide 1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to 52 weeks' open-label add-on detemir (randomized treatment [RT] group; n=162) or continuation without detemir…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00856986

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 987Mar 2009 to Nov 2010

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.